Targeted therapies left out of ASCO breast cancer guideline for now
This article was originally published in Scrip
The American Society of Clinical Oncology (ASCO) released a new treatment guideline on 2 September for women with HER2-negative advanced or metastatic breast cancer that appears to be in line with how doctors already treat patients with later-stage disease and excludes the few available targeted therapies.
You may also be interested in...
Public Company Edition: Five out of six drug developers and a CRO have seen their values spike immediately after going public this month. Also, Moderna floats a $500m offering, Revance proposes a $20m note sale, and Nestle invests another $200m in Aimmune.
Biohaven is still studying its glutamate modulator in three other indications, but its biggest near-term milestone will be approval of the oral CGRP inhibitor rimegepant for acute migraine.
Despite positive Phase III results in Lennox-Gastaut syndrome, the effect of the company’s low-dose fenfluramine on serious seizures may not be as good as seen with GW Pharma’s Epidiolex.